fbpx
 Cancer Drug Patents Expiring 2024-2028

Cancer Drug Patents Expiring 2024-2028

0

The fiercely competitive nature of the oncology industry makes the companies invest heavily in research and development to bring in top cancer-treating drug patents. Consequently, the expiration of patents for cancer drugs creates significant opportunities for companies specializing in generic medications.

Identifying these patents can help enterprises expand and diversify their generic drug portfolios. This strategic move reduces dependence on a single drug or product and proactively mitigates risk by diversifying drug portfolios.

Furthermore, this comprehensive list offers crucial insights such as the active ingredient, applicant, and route – vital information for generic drug manufacturers aiming to enter the cancer treatment market strategically. For instance, the route detail guides formulation strategies, ensuring that generic versions align with the original drug’s delivery method for therapeutic equivalence.

Access the Full Report:

While this article highlights key details, you can obtain the complete PDF version of “Cancer Drug Patents Expiring in 2024-2028” by simply filling out the form below. Don’t miss this opportunity to stay ahead in the dynamic pharmaceutical landscape.

Abraxane
Paclitaxel

Applicant:
Bristol-Myers Squibb Co

PatentsExpiration Date
US77588912026-02-21
US78207882024-10-27
US80343752026-08-13
US82683482026-02-21
US91015432026-02-21

Ingredients: Paclitaxel
Route: Powder; Intravenous

Akeega
Abiraterone Acetate; Niraparib Tosylate

Applicant:
Janssen Biotech Inc

PatentsExpiration Date
US80715792027-08-12
US81432412027-08-12

Ingredients: Abiraterone Acetate; Niraparib Tosylate
Route: Tablet; Oral

Beleodaq
Belinostat

Applicant:
Acrotech Biopharma Inc

PatentsExpiration Date
US68880272026-08-10

Ingredients: Belinostat
Route: Powder; Intravenous

Belrapzo
Bendamustine Hydrochloride

Applicant:
Eagle Pharmaceuticals Inc

PatentsExpiration Date
US87912702026-01-12

Ingredients: Bendamustine Hydrochloride
Route: Solution; Intravenous

Bendeka
Bendamustine Hydrochloride

Applicant:
Eagle Pharmaceuticals Inc

PatentsExpiration Date
US87912702026-01-12

Ingredients: Bendamustine Hydrochloride
Route: Solution; IV (Infusion)

Erivedge
Vismodegib

Applicant:
Genentech Inc

PatentsExpiration Date
US92789612028-12-15

Ingredients: Vismodegib

Route: Capsule; Oral

Erleada
Apalutamide

Applicant:
Janssen Biotech Inc

PatentsExpiration Date
US88026892027-03-27

Ingredients: Apalutamide
Route: Tablet; Oral

Folotyn
Pralatrexate

Applicant:
Acrotech Biopharma Inc

PatentsExpiration Date
US76224702025-05-31

Ingredients: Pralatrexate
Route: Solution; Intravenous

Gilotrif
Afatinib Dimaleate

Applicant:
Boehringer Ingelheim

PatentsExpiration Date
US95392582026-11-09

Ingredients: Afatinib Dimaleate
Route: Tablet; Oral

Imbruvica
Ibrutinib

Applicant:
Pharmacyclics LLC

PatentsExpiration Date
US84762842026-12-28
US84762842026-12-28
US84762842026-12-28
US84972772026-12-28
US85635632027-04-26
US89520152026-12-28
US89520152026-12-28
US89520152026-12-28
US89520152026-12-28
US89520152026-12-28

Ingredients: Ibrutinib

Route: Capsule and Tablet; Oral

Ixempra Kit
Ixabepilone

Applicant:
R-Pharm US LLC

PatentsExpiration Date
US73122372024-08-21

Ingredients: Ixabepilone
Route: Injectable; Intravenous

Lazanda
Fentanyl Citrate

Applicant:
BTCP Pharma Llc

PatentsExpiration Date
US82166042024-10-03
US88891762024-01-16

Ingredients: Fentanyl Citrate
Route: Spray, Metered; Nasal

Lenvima
Lenvatinib Mesylate

Applicant:
Eisai Inc

PatentsExpiration Date
US90062562027-07-27

Ingredients: Lenvatinib Mesylate
Route: Capsule; Oral

Locametz
Gallium Ga-68 Gozetotide

Applicant:
Novartis Pharmaceuticals Corp

PatentsExpiration Date
US113695902028-08-15

Ingredients: Gallium Ga-68 Gozetotide
Route: Powder; Intravenous

Lonsurf
Tipiracil Hydrochloride; Trifluridine

Applicant:
Taiho Oncology Inc

PatentsExpiration Date
US77997832026-12-16

Ingredients: Tipiracil Hydrochloride; Trifluridine
Route: Tablet; Oral

Lynparza
Olaparib

Applicant:
Astrazeneca Pharmaceuticals LP

PatentsExpiration Date
US80715792027-08-12
US80715792027-08-12
US81432412027-08-12
US81432412027-08-12
US89121872024-03-12
US89121872024-03-12
US89121872024-03-12
US91692352024-03-12
US91692352024-03-12

Ingredients: Olaparib
Route: Tablet; Oral and Capsule; Oral

Mekinist
Trametinib Dimethyl Sulfoxide

Applicant:
Novartis Pharmaceuticals Corp

PatentsExpiration Date
US88354432025-06-10

Ingredients: Trametinib Dimethyl Sulfoxide
Route: Tablet; Oral

Nerlynx
Neratinib Maleate

Applicant:
Puma Biotechnology Inc

PatentsExpiration Date
US100357882028-10-15
US79820432025-10-08
US91395582028-10-15
US96309462028-10-15

Ingredients: Neratinib Maleate
Route: Tablet; Oral

Onivyde
Irinotecan Hydrochloride

Applicant:
Ipsen Biopharmaceuticals Inc

PatentsExpiration Date
US87031812025-05-02

Ingredients: Irinotecan Hydrochloride
Route: Injectable, Liposomal; Intravenous

Onsolis
Fentanyl Citrate

Applicant:
Adalvo Ltd

PatentsExpiration Date
US95792882027-07-23
US95972882027-07-23

Ingredients: Fentanyl Citrate
Route: Film; Buccal

Orgovyx
Relugolix

Applicant:
Sumitomo Pharma Switzerland Gmbh

PatentsExpiration Date
US87354012024-02-04

Ingredients: Relugolix
Route: Tablet; Oral

Orserdu
Elacestrant Dihydrochloride

Applicant:
Stemline Therapeutics Inc

PatentsExpiration Date
US76121142026-08-18
US83995202024-12-25

Ingredients: Elacestrant Dihydrochloride
Route: Tablet; Oral

Pluvicto
Lutetium Lu-177 Vipivotide Tetraxetan

Applicant:
Novartis Pharmaceuticals Corp

PatentsExpiration Date
US104062402028-08-15
US113181212028-08-15

Ingredients: Lutetium Lu-177 Vipivotide Tetraxetan
Route: Solution; Intravenous

Revlimid
Lenalidomide

Applicant:
Bristol Myers Squibb

PatentsExpiration Date
US87419292028-03-08

Ingredients: Lenalidomide
Route: Capsule; Oral

Rozlytrek
Entrectinib

Applicant:
Genentech Inc

PatentsExpiration Date
US86738932028-07-08
US92550872028-07-08

Ingredients: Entrectinib
Route: Capsule; Oral

Rubraca
Rucaparib Camsylate

Applicant:
Zr Pharma And Gmbh

PatentsExpiration Date
US73517012024-07-23
US75315302024-07-23
US80715792027-08-12
US81432412027-08-12

Ingredients: Rucaparib Camsylate
Route: Tablet; Oral

Tepmetko
Tepotinib Hydrochloride

Applicant:
EMD Serono Inc

PatentsExpiration Date
US86586432028-07-04
US89275402028-07-21
US94037992028-07-04

Ingredients: Tepotinib Hydrochloride
Route: Tablet; Oral

Treanda
Bendamustine Hydrochloride

Applicant:
Cephalon Inc

PatentsExpiration Date
US87912702026-01-12
US87912702026-01-12

Ingredients: Bendamustine Hydrochloride
Route: Powder; Iv (Infusion)

Tukysa
Tucatinib

Applicant:
Seagen Inc

PatentsExpiration Date
US74528952024-11-16
US96939892027-05-09

Ingredients: Tucatinib
Route: Tablet; Oral

Valchlor
Mechlorethamine Hydrochloride

Applicant:
Helsinn Birex Pharmaceuticals Ltd

PatentsExpiration Date
US85018192026-03-07

Ingredients: Mechlorethamine Hydrochloride
Route: Gel;Topical

Varubi
Rolapitant Hydrochloride

Applicant:
Tersera Therapeutics LLC

PatentsExpiration Date
US70493202028-08-19
US70493202028-08-19
US79819052027-04-04
US79819052027-04-04
US84047022027-04-04
US84047022027-04-04

Ingredients: Rolapitant Hydrochloride
Route: Emulsion; Intravenous and Tablet; Oral

Vizimpro
Dacomitinib

Applicant:
Pfizer Inc

PatentsExpiration Date
US86238832025-05-05

Ingredients: Dacomitinib
Route: Tablet; Oral

Xalkori
Crizotinib

Applicant:
PF Prism CV

PatentsExpiration Date
US78251372027-05-12
US78251372027-05-12

Ingredients: Crizotinib
Route: Capsule and Capsule, Pellets; Oral

Xtandi
Enzalutamide

Applicant:
Astellas Pharma US Inc

PatentsExpiration Date
US81832742026-08-24
US81832742026-08-24
US81832742026-08-24
US91269412026-05-15
US91269412026-05-15

Ingredients: Enzalutamide
Route: Capsule and Tablet; Oral

Zejula
Niraparib Tosylate

Applicant:
Glaxosmithkline LLC

PatentsExpiration Date
US80715792027-08-12
US80715792027-08-12
US81432412027-08-12
US81432412027-08-12

Ingredients: Niraparib Tosylate
Route: Capsule and Tablet; Oral

Zolinza
Vorinostat

Applicant:
Merck Sharp And Dohme LLC (A Sub Of Merck And Co Inc)

PatentsExpiration Date
US73997872025-02-09
US78515092024-02-21
US84503722028-03-18

Ingredients: Vorinostat
Route: Capsule; Oral

Zydelig
Idelalisib

Applicant:
Gilead Sciences Inc

PatentsExpiration Date
USRE445992025-07-21

Ingredients: Idelalisib
Route: Tablet; Oral

Zykadia
Ceritinib

Applicant:
Novartis Pharmaceuticals Corp

PatentsExpiration Date
US83779212027-11-20
US83779212027-11-20

Ingredients: Ceritinib
Route: Capsule and Tablet; Oral

Zytiga
Abiraterone Acetate

Applicant:
Janssen Biotech Inc

Patents Expiration Date
US8822438 2027-08-24
US8822438 2027-08-24

Ingredients: Abiraterone Acetate
Route: Tablet; Oral

Conclusion

As a drug patent expires, it expands the gateway for a number of competitors to enter the market. Tracking these patent expirations beforehand using Pharsight can not only help evaluate business opportunities but also help in refining market entry strategies. 

However, there still lie legal and technology threats and hurdles that a generic company will face depending on the drug they choose for the generic version.

The most recent example is the antitrust lawsuit against Natco Pharma and other generic drug manufacturers regarding the anti-cancer treatment medication Pomalidomide. Although the case was dismissed, the company’s shares fell significantly, causing a considerable negative impact on the company. Therefore, if proper research and threat analysis were conducted, developing a generic version of the medication wouldn’t be as daunting.

How to go about it? 

Well, let’s start with getting in touch.

Connect with an expert

Authored by: Annie Sharma, Editorial Team

Insights by: Nikhil Kaushal, Product Development Team

Leave a Comment

Become a part of GreyB’s insider list

Get our distilled learning delivered to you.

Get the Sample Report

Fill out the form and get the report.